TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 potential as an individualized cancer immunotherapy ...
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced the appointment of two additional key scientific ...
Transgene Further Strengthens Scientific Advisory Board with Appointments of Renowned Cancer Immunotherapy ExpertsAntoine Italiano and Ignacio Melero Strasbourg, France, January 23, 2026, 8:00 a.m.
Strasbourg, France, January 23, 2026, 8:00 a.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced th ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results